Torrent Pharmaceuticals (TORNTPHARM) — Board Meeting

Torrent Pharmaceuticals reported H1 FY26 revenue of ₹6,480 crores (up 13% YoY) with net profit of ₹1,139 crores (up 25% YoY). Q2 standalone revenue reached ₹2,762 crores and net profit ₹597 crores. Operating EBITDA grew 15% YoY to ₹1,083 crores with margin expansion to 32.8%. Geographic strength includes India (12%), Brazil (21%), and US (26%) growth. Total assets increased to ₹15,515 crores with debt-to-equity ratio improving to 0.24. Board approved acquisition of J.B. Chemicals & Pharmaceuticals Limited.

📄 View Original Announcement (PDF)

📊 Stock Analysis — TORNTPHARM ✨ Ask AI About This

About Torrent Pharmaceuticals Limited (TORNTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,49,108.91 Cr P/E: 80.1

View full TORNTPHARM stock details →

📡 Get AI alerts when TORNTPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track TORNTPHARM — Free

💡 Ask AI about this filing

"How does this board meeting affect Torrent Pharmaceuticals Limited's outlook?" "What did Torrent Pharmaceuticals Limited announce on 7 November 2025?" "Is this positive or negative for TORNTPHARM?"

Ask AI Free →

📊 More TORNTPHARM filings

See all TORNTPHARM filings →

🔥 Also filed on 7 November 2025

APOLLOHOSP Apollo Hospitals Enterprise Limited Financial Results BAJAJ-AUTO Bajaj Auto Limited Announcement ZYDUSLIFE Zydus Lifesciences Limited Financial Results TRENT Trent Limited Financial Results TRENT Trent Limited Financial Results BAJAJ-AUTO Bajaj Auto Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TORNTPHARM files new disclosures

Track TORNTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.